Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Senegal has been steadily increasing over the years.
Customer preferences: Patients suffering from autoimmune diseases, such as lupus and rheumatoid arthritis, are the primary consumers of immunosuppressants in Senegal. These patients require long-term treatment with these drugs to manage their conditions. Additionally, organ transplant recipients also require immunosuppressants to prevent their bodies from rejecting the transplanted organs.
Trends in the market: The market for immunosuppressants in Senegal has been growing due to the increasing prevalence of autoimmune diseases and organ transplant procedures. The government has also been taking steps to improve access to healthcare, which has resulted in more people seeking treatment for their conditions. Furthermore, there has been an increase in the availability of generic immunosuppressants, which has made these drugs more affordable for patients.
Local special circumstances: One of the challenges faced by the immunosuppressants market in Senegal is the lack of healthcare infrastructure in certain parts of the country. This makes it difficult for patients in these areas to access the drugs they need. Additionally, there is a lack of awareness among the general population about autoimmune diseases, which can lead to delays in diagnosis and treatment.
Underlying macroeconomic factors: Senegal's economy has been growing steadily over the years, which has led to an increase in disposable income among the population. This has resulted in more people being able to afford healthcare and medication. The government has also been investing in the healthcare sector, which has led to the development of better healthcare facilities and the recruitment of more healthcare professionals. These factors are expected to continue to drive the growth of the immunosuppressants market in Senegal in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
